{"ticker": {"uuid": "918e8a8f-6a79-44de-97d5-69c0a0d00ca0", "symbol": "LYEL", "name": "Lyell Immunopharma Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Form S-3 Lyell Immunopharma Inc For: 13 July By Investing.com", "summary": "This article announces that Lyell Immunopharma Inc. filed a Form S-3 on July 13. The filing is brief and includes a stock performance update for LYEL, which was down 4.53%. The text also contains various financial market data and unrelated popular news.", "url": "https://ng.investing.com/news/stock-market-news/form-s3-lyell-immunopharma-inc-for-13-july-93CH-2597655", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T00:40:26", "published_display": "14 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma Files for Secondary Offering of Common Shares", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/lyell-immunopharma-files-secondary-offering-213000036.html", "source_name": "MT Newswires", "published_at": "2026-07-13T21:30:00+00:00", "published_display": "13 Jul 2026 21:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (NASDAQ: LYEL) files resale shelf for 1.1M shares", "summary": "Lyell Immunopharma (NASDAQ: LYEL) has filed an S-3 shelf registration statement for the resale of up to 1.1 million shares of common stock by Innovative Cellular Therapeutics Holdings Limited (ICT Holdings). Lyell will not receive any proceeds from these sales, which stem from an", "url": "https://www.stocktitan.net/sec-filings/LYEL/s-3-lyell-immunopharma-inc-shelf-registration-statement-9cc7cc331b97.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:43:25", "published_display": "13 Jul 2026 21:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Two US-Listed Stocks Gaining Upside Momentum as Russell 3000 Traded Higher- LYEL, BBAI", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPMkF3aUpRcWY3TG1CVjRtcWhHT0lmOUcxXzhZTE52M2lUWnJiLXk2VGc0eUp5Z3NPWkQ0aFEwWlZFdkMtQ2JXQWstejdha01uR09rQWctVGNxQnJ5MUY5ZXBQMURjeVA5OHFOVjNiaGxxS3VMaWhNdUhVejBLcU9qRlJHR2U3emQ1Y1JXSGpOTXY2QUF0TjkyTm1iWUhuWXhnTFdCNGZuVDIyVnkwOTNsb1g2TGxyQQ?oc=5", "source_name": "Kalkine", "published_at": "2026-07-04T03:48:21+00:00", "published_display": "04 Jul 2026 03:48", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma updates pipeline strategy as cell therapy field evolves", "summary": "Lyell Immunopharma is refining its cell therapy pipeline and manufacturing approach to enhance T cell function and persistence in treating solid tumors. The company focuses on addressing T cell exhaustion and dysfunction, aiming to compete with other immuno-oncology modalities. A", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/lyell-immunopharma-updates-pipeline-strategy-as-cell-therapy-field-evolves/69680937", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T14:58:51", "published_display": "03 Jul 2026 14:58", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LYEL - Lyell Immunopharma Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Lyell Immunopharma Inc (LYEL), including its stock performance, key financial metrics, volatility indicators, and ownership data. It presents a snapshot of the company's market capitalization, income, sales, earnings per shar", "url": "https://finviz.com/stock?t=LYEL&ta=1&p=d&ty=ocv&r=m3&ov=list_strike&s=24", "source_name": "Finviz", "published_at": "2026-07-02T17:40:51", "published_display": "02 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNb050ZmJlQkk4WmFkSFFRZ3cxRlBZaU90bld5MHRJdVRXZVd5em9LdFRfeU1nUmNSQnVvVkc4WFNZYzRJd2k4NFQzTFhxZkJaaWhEY1V3dGpqNjVmSmxqYVk5SE1MYUJGNDZ4SUZXWENsLTFSZXhFaTNTczVTdVBSdzB1QWhRejhGY1RXV1g2dDhFUjY3cEJPWWp0VjlwQQ?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Lyell Immunopharma Inc For: 1 July By Investing.com", "summary": "This article reports a Form 4 filing for Lyell Immunopharma Inc. on July 1st, highlighting the company's stock symbol LYEL. It notes a 4.55% increase for the stock, indicating recent market activity for the company.", "url": "https://za.investing.com/news/stock-market-news/form-4-lyell-immunopharma-inc-for-1-july-93CH-4352434", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T17:14:58", "published_display": "01 Jul 2026 17:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovative Cellular Therapeutics moves 76K Lyell (LYEL) shares as broker commission", "summary": "Innovative Cellular Therapeutics Holdings Ltd, a major shareholder of Lyell Immunopharma, Inc., transferred 76,000 shares of Lyell common stock to Wuxiong, Inc. as a broker commission related to an upfront payment under a license agreement. This \"other\" transaction, which involve", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-4-lyell-immunopharma-inc-insider-trading-activity-be747f9d9f86.html", "source_name": "Stock Titan", "published_at": "2026-07-01T16:09:37", "published_display": "01 Jul 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma stock maintained at Market Outperform by Citizens", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQR1gzWmdCamU3cktZREtyRlVscmNTUTRqNzJHanpzc0FjeGRsSkpoZmNydnpENm0tcnZ5cHVSQTBiWGtXdHU1QTlZeHgzYkV5ZE84NlIyOFNOaHpEV2JQV0ItVGhFVUExcHhsQ0FCZ2ljRHo0dVBjQm5BZE54RUZodmdCQzNtQ2dxV0pxalMybWExTThsMnNLeHZFQWZTelNPblRoTS16QTRYZC04cmdvckdqZXpVX1RjdzNwdDBqNG9pYmdHVjJJ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma, Inc. Actuals & Estimates (NASDAQ:LYEL)", "summary": "This article provides an overview of Lyell Immunopharma, Inc. (NASDAQ: LYEL) stock performance, financial estimates, and analyst forecasts. It includes details on recent price changes, volatility, market capitalization, earnings reports, and future revenue and earnings prediction", "url": "https://www.tradingview.com/symbols/NASDAQ-LYEL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:39:35", "published_display": "26 Jun 2026 02:39", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LYEL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and price target for Lyell Immunopharma, Inc. (LYEL) stock, incorporating analyst opinions, historical performance data, and financial metrics. It covers various aspects including current stock price, volatility, market capitalization, ea", "url": "https://www.tradingview.com/symbols/NASDAQ-LYEL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T23:11:55", "published_display": "25 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LYEL Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides a financial overview of Lyell Immunopharma Inc (LYEL), detailing its revenue breakdown, profitability margins, and a comparison with competitors. LYEL maintains a gross margin of 100.00% but reports negative operating and net margins, indicating challenges i", "url": "https://intellectia.ai/en/stock/LYEL/financials", "source_name": "Intellectia AI", "published_at": "2026-06-25T23:09:48", "published_display": "25 Jun 2026 23:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Lyell Immunopharma Inc For: 24 June By Investing.com", "summary": "The article reports on a Form 4 filing for Lyell Immunopharma Inc. dated June 24. This filing is related to insider trading information for the company (ticker: LYEL), which saw a 2.93% increase in its stock price. The content is presented by Investing.com, a financial markets pl", "url": "https://ca.investing.com/news/stock-market-news/form-4-lyell-immunopharma-inc-for-24-june-93CH-4705869", "source_name": "Investing.com Canada", "published_at": "2026-06-25T16:09:48", "published_display": "25 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference", "summary": "Lyell Immunopharma will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The company's President and CEO, Charles Hessey, is scheduled to present on July 1, 2026. A webcast of the presentation will be available on the Lyell website.", "url": "https://www.moomoo.com/news/post/72035895/lyell-immunopharma-announces-participation-in-hc-wainwright-4th-annual-cell", "source_name": "Moomoo", "published_at": "2026-06-25T13:40:15", "published_display": "25 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovative Cellular Therapeutics (LYEL) crosses 12.3% ownership after milestone", "summary": "Innovative Cellular Therapeutics Holdings Limited has reported beneficial ownership of 3,000,000 shares of Lyell Immunopharma (LYEL) common stock, representing approximately 12.3% of the class. This increase in ownership, detailed in an amended Schedule 13G/A filing, occurred aft", "url": "https://www.stocktitan.net/sec-filings/LYEL/schedule-13g-a-lyell-immunopharma-inc-amended-passive-investment-disc-5fe6eed12bff.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:32:18", "published_display": "18 Jun 2026 20:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovative Cellular Therapeutics (LYEL partner) reports 3M Lyell Immunopharma shares", "summary": "Innovative Cellular Therapeutics Holdings Ltd has filed an initial statement of beneficial ownership, reporting a holding of 3,000,000 common shares of Lyell Immunopharma, Inc. This stake arises from a License Agreement between the two companies, with 1.9 million shares received ", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-3-lyell-immunopharma-inc-initial-statement-of-beneficial-ownersh-e9db338505b2.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:10:18", "published_display": "18 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) major holder transfers shares as commission", "summary": "Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma (LYEL), transferred 66,500 shares of common stock to LifeSci Advisors, LLC as broker commission on June 15, 2026. This transfer, made for no cash consideration, was tied to an upfront payment under a", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-4-lyell-immunopharma-inc-insider-trading-activity-3835707700c8.html", "source_name": "Stock Titan", "published_at": "2026-06-18T01:40:18", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma Inc (LYEL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Lyell Immunopharma Inc (LYEL), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that Lyell's score is 7.67, ranking 276 out of 388 in the Biotechnology & Medical Research industr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lyel/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:58", "published_display": "17 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma president and CEO Lynn Seely sells $7,337 in stock", "summary": "Lyell Immunopharma's CEO, Lynn Seely, sold 388 shares worth $7,337, a transaction primarily to cover tax obligations from vested restricted stock units. This occurs as LYEL shares have experienced recent volatility, with a 10% gain over the last week but a 58% decline over six mo", "url": "https://www.investing.com/news/insider-trading-news/lyell-immunopharma-president-and-ceo-lynn-seely-sells-7337-in-stock-93CH-4743536", "source_name": "Investing.com", "published_at": "2026-06-16T09:09:58", "published_display": "16 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma COO Stephen Hill sells $1,683 in shares", "summary": "Stephen J. Hill, COO of Lyell Immunopharma (NASDAQ:LYEL), sold 89 shares totaling $1,683 on May 11, 2026, to cover tax obligations from vested restricted stock units. The sale occurred at an average price of $18.92 per share, significantly above the current stock price of $13.55,", "url": "https://www.investing.com/news/insider-trading-news/lyell-immunopharma-coo-stephen-hill-sells-1683-in-shares-93CH-4743535", "source_name": "Investing.com", "published_at": "2026-06-16T09:09:58", "published_display": "16 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock By Investing.com", "summary": "Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, sold $2,459 worth of LYEL stock on May 11, 2026, to cover tax obligations from vested restricted stock units. Following this, he still holds 17,808 shares. The sale occurred while the biotech company, valued at $315 mill", "url": "https://m.za.investing.com/news/insider-trading-news/lyell-immunopharma-cso-gary-k-lee-sells-2459-in-lyel-stock-93CH-4329469?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-15T23:10:46", "published_display": "15 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) CEO\u2019s 388-share tax-related stock sale detailed in Form 4", "summary": "Lyell Immunopharma (LYEL) CEO Lynn Seely reported a sale of 388 shares of common stock on May 11, 2026, at a weighted average price of $18.91 per share. This transaction was an automatic sale to cover tax withholding obligations from vested restricted stock units, not a discretio", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-4-lyell-immunopharma-inc-insider-trading-activity-076edd67b76c.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:10:46", "published_display": "15 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) CSO reports small tax-driven sale of company shares", "summary": "Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, reported a sale of 130 company shares at a weighted average price of $18.92 per share. This transaction was an automatic sale to cover tax withholding obligations associated with vested restricted stock units, not a disc", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-4-lyell-immunopharma-inc-insider-trading-activity-6b42a2ff4fc7.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:10:46", "published_display": "15 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) VP auto-sells shares to cover RSU tax withholding", "summary": "Veronica Sanchez Bulis, VP and Corporate Controller of Lyell Immunopharma (LYEL), automatically sold 217 shares of company common stock on May 11, 2026. This sale was conducted to cover tax withholding obligations arising from the settlement of vested restricted stock units. Foll", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-4-lyell-immunopharma-inc-insider-trading-activity-756345ed4e16.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:10:46", "published_display": "15 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) COO\u2019s 89-share sale tied to RSU tax withholding", "summary": "Lyell Immunopharma's Chief Operating Officer, Stephen J. Hill, reported an automatic sale of 89 shares of common stock on May 11, 2026, at a weighted average price of $18.92 per share. This sale was conducted to cover tax withholding obligations associated with the vesting of res", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-4-lyell-immunopharma-inc-insider-trading-activity-a5d0e2a273cf.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:10:46", "published_display": "15 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (NASDAQ: LYEL) reports 2026 shareholder meeting and director elections", "summary": "Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the results of its 2026 annual meeting, where shareholders elected three directors\u2014Richard Klausner, M.D., Otis Brawley, M.D., and William Rieflin\u2014with significant support. A quorum was established with 67.31% of outstanding share", "url": "https://www.stocktitan.net/sec-filings/LYEL/8-k-lyell-immunopharma-inc-reports-material-event-433dfb7c5df8.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:10:46", "published_display": "15 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection (NASDAQ:LYEL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNUDE4TzM1MU1XS185cktpOXprdWY0WXY4M2R1RUh5VGMzSTk3cHdldTFoR3QwWlVJNnJrWko2b2hMdlE2bnRTV0NvaVpoU2F6TURWTWZIRWlZUVJaWUplOURrTXRVdHJQOWNmcHpKR3dMdFVrX3NxS2lfNWtOc1Jac0VOdUlmVElCTmE5anNfSVl5Ui1ieUNBdUFMblh0aWt2emZtNFhYekY?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lyell-immunopharma-presents-updated-safety-164500449.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T16:45:00+00:00", "published_display": "12 Jun 2026 16:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) director awarded 9,250 stock options at $13.22", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPVHkwREpRYWI0Tlg2VGJQbEJpN2NqdEtmVmJoa1pSbmpkWFo5YnB2WXlLQVFlSEpUMm9nSy1xcXNId0ZzZDkxbTh3YWx6bmlOcnhCTjF6bDZTcVBjQWFKQmduYUZRb2VVOUZMUml3LVdNQW1WZWlqcE5hMXlyUm9lWmhPb1JDV01DaXExa1Q2S2xGSkRaOTdldGF0ajM4cTdhYXJ1c2xuVGRTWVpQM1NTMFg5dUZvUFU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) director receives option grant for 9,250 shares at $13.22", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQRnpqbkV2U0VhNlFkT3BMUzJiNjNRM1NXYjRvSUszVDU3QnBsdzdpS2xJRThPTE0zaVJqX3g0X3BJSHhCMGl1N2N3U2lTUWlVYXBqYlNGQjR2Y3RWMjFTTk8tekRZdWpSdzNvRTdFWGRha0JGbU5iVUJuTk1oa29FU1lvM0s3MTJRck9FVEZ2VU1VcmVZRDkwc1lMZEhNaGM3alZnS0ZDdFBMaTFnOHAxMG9rOExRQTA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOUnVsNjUyMF9HQzhMWUJOZ0hNczQxM21mLUhtdndJZXJUY1dHaG4wM3dJRDB2RUFCMUhTVEIyTXI0c1NmNkxaTWdJOG1mVld2ZS1hQmEyRm45QXF1VW5XQUFxSDFHLVFMWF95NUVlQ0c0S2ZsV1hWbHdJZzFUeS1hN1l4VUE0SUxfWWpLLXhmNjk1UXdnUmxYUFJPUjhsb0JnWUE?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lyell-immunopharma-apos-cancer-therapy-104644341.html", "source_name": "MT Newswires", "published_at": "2026-06-08T10:46:44+00:00", "published_display": "08 Jun 2026 10:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lyell-immunopharma-provides-safety-profile-100000024.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T10:00:00+00:00", "published_display": "08 Jun 2026 10:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma stock rises on trial amendment", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPMEVSLVE0ZXRFTWVxRHNTUExRRGtleWhBdzBySUl0V1BpVEp1Mmx0azVvemtrbVBxU0VrVVB0Y1VhQm41d3lxR2xxOWtTTUp4UTlZMkxZQ0JVMGxpOVkwbk9RZ1NrMGFsWjhBS2V3S1lFNjJNZjRJSktvM2ZhVkllX0FGSkswdU9CNk04UDZJWTdGTVJrWVZER3FkQWY0Uk5ETkd4WWxpdllETnFtcF9MbQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lyell-immunopharma-present-phase-1-200500558.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T20:05:00+00:00", "published_display": "04 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQWlB6LVpkRDlQOXJIczFod09pQUo5RXlzV3FUd0Joc2oxcmdzMktyYm1kWU5qbVUyWVVUejRJdTY0WGlxMzFVdTl0dl9VSDdMTXhuTE50cWtkTWRxdzJ3QjY4bW5pejFnZEpfRDR5NXNjS2U1bk1lLW5lcXZ3S05nOVFYWG53WHF2SHZmamIyaGpZcnltUnVaV1pJX1pwZw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma, Inc. Stock 12\u2011Month Price Target Cut to $37.17, Implies 150% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNVWdoMVExaXl4QWRZMkNicG5xSEJQNTVtS1FUZDdRMjJhWXAtRXMzdlNPdkk5TzRvZW55YWYxaWh3bER5S1A0TDJBWEotejJyVkhaWGNOeC00YU1RcFJNS1FHcFJ6b1hsN1VrSU9VbktxV0VRMVBBR3JZVURPeVhuaExmSWVrbWxPdm0tWXV0SWNhQkJrLURGMGQwSU5iN0kwNGdWVWxTZ1dVekZfdVBpR1J6d1puUlFQRXZmQkJCM0ZVNnphV08yOVl3R3ZmX0N2ZVlfU3JRYkVERkYy?oc=5", "source_name": "TradingView", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNZkxqS3VLeTdqeTB4Qkw3b2dIcmtteXNpZlVQd3FRdDFrSWFhNjA1eklMSDh4Zkg5WWF3QmRMQk0xN2JvalMyUDBRM1lyN2d5bDllY1JMU0lwVWh0a19FcXpPS0hHMldBUFJDdmg3dG5hVWwtNjlWOFNYWkpVN19DaFVGRngydEhsMUE?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Explore Investments/Jeff Bezos report 6.6% stake in Lyell (LYEL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPTTBJdnpzblQyWVhQVzRXNGpUUDNxOTdqczRtUWRTTVBDb1dCeUY2TGZkbjVzT1RnN1hkdGg4b2lidGdnWElYeDNSQXZrNEpOZDctektIOTRta2o3Y0lVNEpGNGpEMk9pWlk5OGItd29FQU1nMUNFa0J4OVBoXzgyb294Q1RULXBXajVEVjBjd1FjYmg0ckM2eFp5Sl9CQy1FYUh5UFJJRS1GR0NmY2RmbEtEUWdFaTlSTkFEVVFVSGRGWWp4TVBScm85OA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A First Look At Lyell Immunopharma (NASDAQ:LYEL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNN09nSDY2akJhTWR2V19tU2hPZ1RaVDdsbXp0aGM0M3pyVDFESDJCQ2RxODItc3gwTUNlZGZaSmJtMHZMVVBSMHRmTXNwaTRPRklmekdjSWlCYW1HdDNOV21tY0pNTVFJbU5tZGg1M0tXQkgwVE5JUGlxTjVDTWhLVA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lyell Immunopharma Acquires Exclusive Global Rights to a", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwJBVV95cUxNeTBnQkp2cHZsS0lvMGV6YzBQRUNMUXFhTEl3Y1ZZdUtNbWsxQzNiM2pYMFVkenpvZ29sSGtUT05landfbmJBN2JQUkdCcXJsaTZCdkFmOTNZSk9TQ3dxSk1GbUREZDhrWWlIRF9sbWI4Z1lySWZaZWo5NHFCYUpLTFQ3NndXYVFHWmVKUlM0Q1lVeUNmc1BvWDRwYUl2UjFjOGVwTjJESkZEQ2pSQU1ndUZFU2tzVnc3QTVNTFcwLUExRGk2eVdrdkJBT3pKSUk0R1BCWkJON2ZHaTY2QlA0aThDVFdCMFVtb2VlTHBoT0xodXJfU184NjVZUzRmR1pJUTdubzY3ZVl6WkFiYloxaGxLaVlaU3duVHh3cVhnR1RqaXlmRDY3SVdnTU5PdVVlSmJuUkxDcWtGWE9FaG1KaW5vNm1rVEllYjI5OWFJOA?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma, Inc. Secures $100 Million in Private Placement to Advance CAR T-Cell Therapy Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPQy1fYXFpS0VrZU5TYVVocmprNm9JYXZCM0RyS01WaDF3cENiU0V1bnFzRXpidXlna3FiMHNFU2JQcFJ0QzFSM3hNWWMtMWw3bXBoWV9RcHJueGhNLWFVUzJrTHRMdlJKVVNfZG9pd0dCTnlZQ0dmMlQ2MG1YOVRuS2h0Vko5N1lILWhnS0hYbTZwcU1WT0d4VTg1T0ZhR2JkQ01pSEpJQURwclFwSkZvbHFteTJFUGdPd0pEOXRCa1JjNGY2dlhPYzZ0VXpxbTJEZ1E?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-07-25T07:00:00+00:00", "published_display": "25 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAR-T developer Lyell lays off 73 ImmPact staffers, shutters LA facility shortly after acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNbWZLanRvZU96OTVyQklxcm5xbDZ2cDZBTm5McXUtQnNjSXo1bzV1Smx0XzRQUUdkRXM5d25mSkJiRXdUNzNuVU9uTE1NTU44dkpEamxqQUtMU1lBTkM5THhVQkt4UDVoSDEzeHJaaVQzWE13d202VFdhX0hvbVNfZlBEeU9kYi1meTA3aVpwVEpfek5oRXhsQTBwQkdYaFZHbXhQUkR1Zlc5Q0ltYk1hcjdhSWY4NllSc2kwUHVZMA?oc=5", "source_name": "Fierce Pharma", "published_at": "2025-04-07T07:00:00+00:00", "published_display": "07 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Form S-3 Lyell Immunopharma Inc For: 13 July By Investing.com", "summary": "This article announces that Lyell Immunopharma Inc. filed a Form S-3 on July 13. The filing is brief and includes a stock performance update for LYEL, which was down 4.53%. The text also contains various financial market data and unrelated popular news.", "url": "https://ng.investing.com/news/stock-market-news/form-s3-lyell-immunopharma-inc-for-13-july-93CH-2597655", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T00:40:26", "published_display": "14 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma Files for Secondary Offering of Common Shares", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/lyell-immunopharma-files-secondary-offering-213000036.html", "source_name": "MT Newswires", "published_at": "2026-07-13T21:30:00+00:00", "published_display": "13 Jul 2026 21:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (NASDAQ: LYEL) files resale shelf for 1.1M shares", "summary": "Lyell Immunopharma (NASDAQ: LYEL) has filed an S-3 shelf registration statement for the resale of up to 1.1 million shares of common stock by Innovative Cellular Therapeutics Holdings Limited (ICT Holdings). Lyell will not receive any proceeds from these sales, which stem from an", "url": "https://www.stocktitan.net/sec-filings/LYEL/s-3-lyell-immunopharma-inc-shelf-registration-statement-9cc7cc331b97.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:43:25", "published_display": "13 Jul 2026 21:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two US-Listed Stocks Gaining Upside Momentum as Russell 3000 Traded Higher- LYEL, BBAI", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPMkF3aUpRcWY3TG1CVjRtcWhHT0lmOUcxXzhZTE52M2lUWnJiLXk2VGc0eUp5Z3NPWkQ0aFEwWlZFdkMtQ2JXQWstejdha01uR09rQWctVGNxQnJ5MUY5ZXBQMURjeVA5OHFOVjNiaGxxS3VMaWhNdUhVejBLcU9qRlJHR2U3emQ1Y1JXSGpOTXY2QUF0TjkyTm1iWUhuWXhnTFdCNGZuVDIyVnkwOTNsb1g2TGxyQQ?oc=5", "source_name": "Kalkine", "published_at": "2026-07-04T03:48:21+00:00", "published_display": "04 Jul 2026 03:48", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma updates pipeline strategy as cell therapy field evolves", "summary": "Lyell Immunopharma is refining its cell therapy pipeline and manufacturing approach to enhance T cell function and persistence in treating solid tumors. The company focuses on addressing T cell exhaustion and dysfunction, aiming to compete with other immuno-oncology modalities. A", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/lyell-immunopharma-updates-pipeline-strategy-as-cell-therapy-field-evolves/69680937", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T14:58:51", "published_display": "03 Jul 2026 14:58", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LYEL - Lyell Immunopharma Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Lyell Immunopharma Inc (LYEL), including its stock performance, key financial metrics, volatility indicators, and ownership data. It presents a snapshot of the company's market capitalization, income, sales, earnings per shar", "url": "https://finviz.com/stock?t=LYEL&ta=1&p=d&ty=ocv&r=m3&ov=list_strike&s=24", "source_name": "Finviz", "published_at": "2026-07-02T17:40:51", "published_display": "02 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNb050ZmJlQkk4WmFkSFFRZ3cxRlBZaU90bld5MHRJdVRXZVd5em9LdFRfeU1nUmNSQnVvVkc4WFNZYzRJd2k4NFQzTFhxZkJaaWhEY1V3dGpqNjVmSmxqYVk5SE1MYUJGNDZ4SUZXWENsLTFSZXhFaTNTczVTdVBSdzB1QWhRejhGY1RXV1g2dDhFUjY3cEJPWWp0VjlwQQ?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Lyell Immunopharma Inc For: 1 July By Investing.com", "summary": "This article reports a Form 4 filing for Lyell Immunopharma Inc. on July 1st, highlighting the company's stock symbol LYEL. It notes a 4.55% increase for the stock, indicating recent market activity for the company.", "url": "https://za.investing.com/news/stock-market-news/form-4-lyell-immunopharma-inc-for-1-july-93CH-4352434", "source_name": "Investing.com South Africa", "published_at": "2026-07-01T17:14:58", "published_display": "01 Jul 2026 17:14", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovative Cellular Therapeutics moves 76K Lyell (LYEL) shares as broker commission", "summary": "Innovative Cellular Therapeutics Holdings Ltd, a major shareholder of Lyell Immunopharma, Inc., transferred 76,000 shares of Lyell common stock to Wuxiong, Inc. as a broker commission related to an upfront payment under a license agreement. This \"other\" transaction, which involve", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-4-lyell-immunopharma-inc-insider-trading-activity-be747f9d9f86.html", "source_name": "Stock Titan", "published_at": "2026-07-01T16:09:37", "published_display": "01 Jul 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma stock maintained at Market Outperform by Citizens", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQR1gzWmdCamU3cktZREtyRlVscmNTUTRqNzJHanpzc0FjeGRsSkpoZmNydnpENm0tcnZ5cHVSQTBiWGtXdHU1QTlZeHgzYkV5ZE84NlIyOFNOaHpEV2JQV0ItVGhFVUExcHhsQ0FCZ2ljRHo0dVBjQm5BZE54RUZodmdCQzNtQ2dxV0pxalMybWExTThsMnNLeHZFQWZTelNPblRoTS16QTRYZC04cmdvckdqZXpVX1RjdzNwdDBqNG9pYmdHVjJJ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma, Inc. Actuals & Estimates (NASDAQ:LYEL)", "summary": "This article provides an overview of Lyell Immunopharma, Inc. (NASDAQ: LYEL) stock performance, financial estimates, and analyst forecasts. It includes details on recent price changes, volatility, market capitalization, earnings reports, and future revenue and earnings prediction", "url": "https://www.tradingview.com/symbols/NASDAQ-LYEL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T02:39:35", "published_display": "26 Jun 2026 02:39", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LYEL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and price target for Lyell Immunopharma, Inc. (LYEL) stock, incorporating analyst opinions, historical performance data, and financial metrics. It covers various aspects including current stock price, volatility, market capitalization, ea", "url": "https://www.tradingview.com/symbols/NASDAQ-LYEL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T23:11:55", "published_display": "25 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LYEL Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides a financial overview of Lyell Immunopharma Inc (LYEL), detailing its revenue breakdown, profitability margins, and a comparison with competitors. LYEL maintains a gross margin of 100.00% but reports negative operating and net margins, indicating challenges i", "url": "https://intellectia.ai/en/stock/LYEL/financials", "source_name": "Intellectia AI", "published_at": "2026-06-25T23:09:48", "published_display": "25 Jun 2026 23:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Lyell Immunopharma Inc For: 24 June By Investing.com", "summary": "The article reports on a Form 4 filing for Lyell Immunopharma Inc. dated June 24. This filing is related to insider trading information for the company (ticker: LYEL), which saw a 2.93% increase in its stock price. The content is presented by Investing.com, a financial markets pl", "url": "https://ca.investing.com/news/stock-market-news/form-4-lyell-immunopharma-inc-for-24-june-93CH-4705869", "source_name": "Investing.com Canada", "published_at": "2026-06-25T16:09:48", "published_display": "25 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference", "summary": "Lyell Immunopharma will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The company's President and CEO, Charles Hessey, is scheduled to present on July 1, 2026. A webcast of the presentation will be available on the Lyell website.", "url": "https://www.moomoo.com/news/post/72035895/lyell-immunopharma-announces-participation-in-hc-wainwright-4th-annual-cell", "source_name": "Moomoo", "published_at": "2026-06-25T13:40:15", "published_display": "25 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovative Cellular Therapeutics (LYEL) crosses 12.3% ownership after milestone", "summary": "Innovative Cellular Therapeutics Holdings Limited has reported beneficial ownership of 3,000,000 shares of Lyell Immunopharma (LYEL) common stock, representing approximately 12.3% of the class. This increase in ownership, detailed in an amended Schedule 13G/A filing, occurred aft", "url": "https://www.stocktitan.net/sec-filings/LYEL/schedule-13g-a-lyell-immunopharma-inc-amended-passive-investment-disc-5fe6eed12bff.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:32:18", "published_display": "18 Jun 2026 20:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Innovative Cellular Therapeutics (LYEL partner) reports 3M Lyell Immunopharma shares", "summary": "Innovative Cellular Therapeutics Holdings Ltd has filed an initial statement of beneficial ownership, reporting a holding of 3,000,000 common shares of Lyell Immunopharma, Inc. This stake arises from a License Agreement between the two companies, with 1.9 million shares received ", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-3-lyell-immunopharma-inc-initial-statement-of-beneficial-ownersh-e9db338505b2.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:10:18", "published_display": "18 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) major holder transfers shares as commission", "summary": "Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma (LYEL), transferred 66,500 shares of common stock to LifeSci Advisors, LLC as broker commission on June 15, 2026. This transfer, made for no cash consideration, was tied to an upfront payment under a", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-4-lyell-immunopharma-inc-insider-trading-activity-3835707700c8.html", "source_name": "Stock Titan", "published_at": "2026-06-18T01:40:18", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma Inc (LYEL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Lyell Immunopharma Inc (LYEL), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that Lyell's score is 7.67, ranking 276 out of 388 in the Biotechnology & Medical Research industr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lyel/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:58", "published_display": "17 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma president and CEO Lynn Seely sells $7,337 in stock", "summary": "Lyell Immunopharma's CEO, Lynn Seely, sold 388 shares worth $7,337, a transaction primarily to cover tax obligations from vested restricted stock units. This occurs as LYEL shares have experienced recent volatility, with a 10% gain over the last week but a 58% decline over six mo", "url": "https://www.investing.com/news/insider-trading-news/lyell-immunopharma-president-and-ceo-lynn-seely-sells-7337-in-stock-93CH-4743536", "source_name": "Investing.com", "published_at": "2026-06-16T09:09:58", "published_display": "16 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma COO Stephen Hill sells $1,683 in shares", "summary": "Stephen J. Hill, COO of Lyell Immunopharma (NASDAQ:LYEL), sold 89 shares totaling $1,683 on May 11, 2026, to cover tax obligations from vested restricted stock units. The sale occurred at an average price of $18.92 per share, significantly above the current stock price of $13.55,", "url": "https://www.investing.com/news/insider-trading-news/lyell-immunopharma-coo-stephen-hill-sells-1683-in-shares-93CH-4743535", "source_name": "Investing.com", "published_at": "2026-06-16T09:09:58", "published_display": "16 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock By Investing.com", "summary": "Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, sold $2,459 worth of LYEL stock on May 11, 2026, to cover tax obligations from vested restricted stock units. Following this, he still holds 17,808 shares. The sale occurred while the biotech company, valued at $315 mill", "url": "https://m.za.investing.com/news/insider-trading-news/lyell-immunopharma-cso-gary-k-lee-sells-2459-in-lyel-stock-93CH-4329469?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-15T23:10:46", "published_display": "15 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) CEO\u2019s 388-share tax-related stock sale detailed in Form 4", "summary": "Lyell Immunopharma (LYEL) CEO Lynn Seely reported a sale of 388 shares of common stock on May 11, 2026, at a weighted average price of $18.91 per share. This transaction was an automatic sale to cover tax withholding obligations from vested restricted stock units, not a discretio", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-4-lyell-immunopharma-inc-insider-trading-activity-076edd67b76c.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:10:46", "published_display": "15 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) CSO reports small tax-driven sale of company shares", "summary": "Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, reported a sale of 130 company shares at a weighted average price of $18.92 per share. This transaction was an automatic sale to cover tax withholding obligations associated with vested restricted stock units, not a disc", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-4-lyell-immunopharma-inc-insider-trading-activity-6b42a2ff4fc7.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:10:46", "published_display": "15 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) VP auto-sells shares to cover RSU tax withholding", "summary": "Veronica Sanchez Bulis, VP and Corporate Controller of Lyell Immunopharma (LYEL), automatically sold 217 shares of company common stock on May 11, 2026. This sale was conducted to cover tax withholding obligations arising from the settlement of vested restricted stock units. Foll", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-4-lyell-immunopharma-inc-insider-trading-activity-756345ed4e16.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:10:46", "published_display": "15 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) COO\u2019s 89-share sale tied to RSU tax withholding", "summary": "Lyell Immunopharma's Chief Operating Officer, Stephen J. Hill, reported an automatic sale of 89 shares of common stock on May 11, 2026, at a weighted average price of $18.92 per share. This sale was conducted to cover tax withholding obligations associated with the vesting of res", "url": "https://www.stocktitan.net/sec-filings/LYEL/form-4-lyell-immunopharma-inc-insider-trading-activity-a5d0e2a273cf.html", "source_name": "Stock Titan", "published_at": "2026-06-15T22:10:46", "published_display": "15 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (NASDAQ: LYEL) reports 2026 shareholder meeting and director elections", "summary": "Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the results of its 2026 annual meeting, where shareholders elected three directors\u2014Richard Klausner, M.D., Otis Brawley, M.D., and William Rieflin\u2014with significant support. A quorum was established with 67.31% of outstanding share", "url": "https://www.stocktitan.net/sec-filings/LYEL/8-k-lyell-immunopharma-inc-reports-material-event-433dfb7c5df8.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:10:46", "published_display": "15 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection (NASDAQ:LYEL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNUDE4TzM1MU1XS185cktpOXprdWY0WXY4M2R1RUh5VGMzSTk3cHdldTFoR3QwWlVJNnJrWko2b2hMdlE2bnRTV0NvaVpoU2F6TURWTWZIRWlZUVJaWUplOURrTXRVdHJQOWNmcHpKR3dMdFVrX3NxS2lfNWtOc1Jac0VOdUlmVElCTmE5anNfSVl5Ui1ieUNBdUFMblh0aWt2emZtNFhYekY?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lyell-immunopharma-presents-updated-safety-164500449.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T16:45:00+00:00", "published_display": "12 Jun 2026 16:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) director awarded 9,250 stock options at $13.22", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPVHkwREpRYWI0Tlg2VGJQbEJpN2NqdEtmVmJoa1pSbmpkWFo5YnB2WXlLQVFlSEpUMm9nSy1xcXNId0ZzZDkxbTh3YWx6bmlOcnhCTjF6bDZTcVBjQWFKQmduYUZRb2VVOUZMUml3LVdNQW1WZWlqcE5hMXlyUm9lWmhPb1JDV01DaXExa1Q2S2xGSkRaOTdldGF0ajM4cTdhYXJ1c2xuVGRTWVpQM1NTMFg5dUZvUFU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) director receives option grant for 9,250 shares at $13.22", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQRnpqbkV2U0VhNlFkT3BMUzJiNjNRM1NXYjRvSUszVDU3QnBsdzdpS2xJRThPTE0zaVJqX3g0X3BJSHhCMGl1N2N3U2lTUWlVYXBqYlNGQjR2Y3RWMjFTTk8tekRZdWpSdzNvRTdFWGRha0JGbU5iVUJuTk1oa29FU1lvM0s3MTJRck9FVEZ2VU1VcmVZRDkwc1lMZEhNaGM3alZnS0ZDdFBMaTFnOHAxMG9rOExRQTA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOUnVsNjUyMF9HQzhMWUJOZ0hNczQxM21mLUhtdndJZXJUY1dHaG4wM3dJRDB2RUFCMUhTVEIyTXI0c1NmNkxaTWdJOG1mVld2ZS1hQmEyRm45QXF1VW5XQUFxSDFHLVFMWF95NUVlQ0c0S2ZsV1hWbHdJZzFUeS1hN1l4VUE0SUxfWWpLLXhmNjk1UXdnUmxYUFJPUjhsb0JnWUE?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lyell-immunopharma-apos-cancer-therapy-104644341.html", "source_name": "MT Newswires", "published_at": "2026-06-08T10:46:44+00:00", "published_display": "08 Jun 2026 10:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lyell-immunopharma-provides-safety-profile-100000024.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T10:00:00+00:00", "published_display": "08 Jun 2026 10:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma stock rises on trial amendment", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPMEVSLVE0ZXRFTWVxRHNTUExRRGtleWhBdzBySUl0V1BpVEp1Mmx0azVvemtrbVBxU0VrVVB0Y1VhQm41d3lxR2xxOWtTTUp4UTlZMkxZQ0JVMGxpOVkwbk9RZ1NrMGFsWjhBS2V3S1lFNjJNZjRJSktvM2ZhVkllX0FGSkswdU9CNk04UDZJWTdGTVJrWVZER3FkQWY0Uk5ETkd4WWxpdllETnFtcF9MbQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lyell-immunopharma-present-phase-1-200500558.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T20:05:00+00:00", "published_display": "04 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQWlB6LVpkRDlQOXJIczFod09pQUo5RXlzV3FUd0Joc2oxcmdzMktyYm1kWU5qbVUyWVVUejRJdTY0WGlxMzFVdTl0dl9VSDdMTXhuTE50cWtkTWRxdzJ3QjY4bW5pejFnZEpfRDR5NXNjS2U1bk1lLW5lcXZ3S05nOVFYWG53WHF2SHZmamIyaGpZcnltUnVaV1pJX1pwZw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma, Inc. Stock 12\u2011Month Price Target Cut to $37.17, Implies 150% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNVWdoMVExaXl4QWRZMkNicG5xSEJQNTVtS1FUZDdRMjJhWXAtRXMzdlNPdkk5TzRvZW55YWYxaWh3bER5S1A0TDJBWEotejJyVkhaWGNOeC00YU1RcFJNS1FHcFJ6b1hsN1VrSU9VbktxV0VRMVBBR3JZVURPeVhuaExmSWVrbWxPdm0tWXV0SWNhQkJrLURGMGQwSU5iN0kwNGdWVWxTZ1dVekZfdVBpR1J6d1puUlFQRXZmQkJCM0ZVNnphV08yOVl3R3ZmX0N2ZVlfU3JRYkVERkYy?oc=5", "source_name": "TradingView", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNZkxqS3VLeTdqeTB4Qkw3b2dIcmtteXNpZlVQd3FRdDFrSWFhNjA1eklMSDh4Zkg5WWF3QmRMQk0xN2JvalMyUDBRM1lyN2d5bDllY1JMU0lwVWh0a19FcXpPS0hHMldBUFJDdmg3dG5hVWwtNjlWOFNYWkpVN19DaFVGRngydEhsMUE?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Explore Investments/Jeff Bezos report 6.6% stake in Lyell (LYEL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPTTBJdnpzblQyWVhQVzRXNGpUUDNxOTdqczRtUWRTTVBDb1dCeUY2TGZkbjVzT1RnN1hkdGg4b2lidGdnWElYeDNSQXZrNEpOZDctektIOTRta2o3Y0lVNEpGNGpEMk9pWlk5OGItd29FQU1nMUNFa0J4OVBoXzgyb294Q1RULXBXajVEVjBjd1FjYmg0ckM2eFp5Sl9CQy1FYUh5UFJJRS1GR0NmY2RmbEtEUWdFaTlSTkFEVVFVSGRGWWp4TVBScm85OA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A First Look At Lyell Immunopharma (NASDAQ:LYEL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNN09nSDY2akJhTWR2V19tU2hPZ1RaVDdsbXp0aGM0M3pyVDFESDJCQ2RxODItc3gwTUNlZGZaSmJtMHZMVVBSMHRmTXNwaTRPRklmekdjSWlCYW1HdDNOV21tY0pNTVFJbU5tZGg1M0tXQkgwVE5JUGlxTjVDTWhLVA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma Acquires Exclusive Global Rights to a", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwJBVV95cUxNeTBnQkp2cHZsS0lvMGV6YzBQRUNMUXFhTEl3Y1ZZdUtNbWsxQzNiM2pYMFVkenpvZ29sSGtUT05landfbmJBN2JQUkdCcXJsaTZCdkFmOTNZSk9TQ3dxSk1GbUREZDhrWWlIRF9sbWI4Z1lySWZaZWo5NHFCYUpLTFQ3NndXYVFHWmVKUlM0Q1lVeUNmc1BvWDRwYUl2UjFjOGVwTjJESkZEQ2pSQU1ndUZFU2tzVnc3QTVNTFcwLUExRGk2eVdrdkJBT3pKSUk0R1BCWkJON2ZHaTY2QlA0aThDVFdCMFVtb2VlTHBoT0xodXJfU184NjVZUzRmR1pJUTdubzY3ZVl6WkFiYloxaGxLaVlaU3duVHh3cVhnR1RqaXlmRDY3SVdnTU5PdVVlSmJuUkxDcWtGWE9FaG1KaW5vNm1rVEllYjI5OWFJOA?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lyell Immunopharma, Inc. Secures $100 Million in Private Placement to Advance CAR T-Cell Therapy Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPQy1fYXFpS0VrZU5TYVVocmprNm9JYXZCM0RyS01WaDF3cENiU0V1bnFzRXpidXlna3FiMHNFU2JQcFJ0QzFSM3hNWWMtMWw3bXBoWV9RcHJueGhNLWFVUzJrTHRMdlJKVVNfZG9pd0dCTnlZQ0dmMlQ2MG1YOVRuS2h0Vko5N1lILWhnS0hYbTZwcU1WT0d4VTg1T0ZhR2JkQ01pSEpJQURwclFwSkZvbHFteTJFUGdPd0pEOXRCa1JjNGY2dlhPYzZ0VXpxbTJEZ1E?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-07-25T07:00:00+00:00", "published_display": "25 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CAR-T developer Lyell lays off 73 ImmPact staffers, shutters LA facility shortly after acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNbWZLanRvZU96OTVyQklxcm5xbDZ2cDZBTm5McXUtQnNjSXo1bzV1Smx0XzRQUUdkRXM5d25mSkJiRXdUNzNuVU9uTE1NTU44dkpEamxqQUtMU1lBTkM5THhVQkt4UDVoSDEzeHJaaVQzWE13d202VFdhX0hvbVNfZlBEeU9kYi1meTA3aVpwVEpfek5oRXhsQTBwQkdYaFZHbXhQUkR1Zlc5Q0ltYk1hcjdhSWY4NllSc2kwUHVZMA?oc=5", "source_name": "Fierce Pharma", "published_at": "2025-04-07T07:00:00+00:00", "published_display": "07 Apr 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 53, "sentiment_summary": {"positive": 13, "negative": 5, "neutral": 35, "score": 53, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 18.3, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 13, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 15.01, "latest_week": "2026-07-10", "one_week_move": 6.8, "four_week_move": 11.2, "twelve_week_move": -37.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.823082, "market_dynamics_buy_signal": false, "relative_strength": -31.979581, "fair_value_gap": -42.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.3804, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.8% over one week, +11.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "Market source", "count": 9}, {"label": "Investing.com", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "MT Newswires", "count": 2}, {"label": "Investing.com South Africa", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+6.8% over one week, +11.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Form S-3 Lyell Immunopharma Inc For: 13 July By Investing.com"}], "updated_at": "2026-07-16T08:11:16.901647+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}